U.S.-CHINA PHARMA: Shrewd Strategies for Mining Profits from Pharma Opportunities in China

Date

Start: Monday, May 20, 2013 @ 8:00 AM (+00:00)

Address
Martin Conference Center at Harvard Medical School 77 Avenue Louis Pasteur
Boston , MA 02115
Organizer's Website

http://www.regonline.com/USChinaPharma2013

About This Activity



 
Join U.S.-CHINA PHARMA and meet face-to-face with hundreds of visionaries who are shaping the future R&D landscape between the United States and China. Compare and explore different discovery operations and approaches, and learn about best practices and strategies in leveraging partnerships, alliances, collaborations, outsourcing, and in-licensing to bring a drug from bench to clinic cheaper and faster. Join today and walk away with partners for your next project.
Hot Topics for 2011: Identify R&D strategies to cost-effectively expand product portfolios • New approaches to feed R&D pipelines through academic/industry partnerships  • Clinical and translational strategies in the area of biomarker research • Emerging business models for R&D partnerships and their impact on the pharmaceutical and biotech industries • Role of technology transfer and licensing, and assess potential investment opportunities  • Suitable entities for preclinical and clinical outsourcing
Prices and discounts

Your Registration Fee Covers:
  • Unlimited access to all workshops, presentations, and panel discussions
  • Networking events including receptions or dinners during the conference
  • Admission to the exhibition area
  • Breakfast, lunch, and refreshments
  • On-site materials
 Pricing  Book and Pay by
 12/15/10
 Book and Pay by
 3/16/11
 Book and Pay by
 5/18/11
 Standard Price
 Regular Admission  (SAVE $400)
 $1,299
 (SAVE $300)
 $1,399
 (SAVE $200)
 $1,499
 $1,699
 Academic
 Government,
 NGOs
 (SAVE $250)
 $625
 (SAVE $150)
 $725
 (SAVE $50)
 $825
 $875

*Payments must be made before the cut-off date in order to receive any discounts.
Please read our conference registration terms and conditions.

 

Discuss This Activity

This activity has passed